NCT01039233已完成1 期
Randomized, Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex 50 mg Tablet Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions
Kremers Urban Development Company1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2005年5月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration)
研究概览
简要总结
The objective of this study is to compare the rate and extent of absorption of bicalutamide 50 mg tablet (test) versus Casodex (reference), administered as 1 x 50 mg tablet under fasting conditions
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 73 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Male, non-smoker, 18 years of age and older;
- •Capable of consent;
- •BMI≥19.0 and <30.0 kg/m2.
排除标准
- •Clinically significant illnesses within 4 weeks prior to the administration of the study medication.
- •Clinically significant surgery within 4 weeks prior to the administration of the study medication.
- •Any clinically significant abnormality found during medical screening.
- •Any reason which, in the opinion of the Medical Sub-Investigator, would prevent the subject from participating in the study.
- •Abnormal laboratory tests judged clinically significant.
- •Positive testing for hepatitis B, hepatitis C, or HIV at screening.
- •ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.
- •History of significant alcohol abuse or drug abuse within one year prior to the screening visit.
- •Regular use of alcohol within six months prior to the screening visit (more than fourteen units of alcohol per week [1 Unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]).
- •Use of soft drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs (such as cocaine, phencyclidine [PCP] and crack) within 1 year prior to the screening visit or positive urine drug screen at screening.
- •Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole; examples of inhibitors: antidepressants (SSRI), cimetidine, diltiazem, macrolides, imidazoles, neuroleptics, verapamil, fluoroquinolones, antihistamines) within 30 days prior to administration of the study medication.
- •Use of an investigational drug or participation in an investigational study within 30 days prior to administration of the study medication.
- •Clinically significant history or presence of any clinically significant gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases), unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of the drug.
- •Any clinically significant history or presence of clinically significant neurological, endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric, or metabolic disease.
- •Use of prescription medication within 14 days prior to administration of study medication or over-the-counter products (including natural food supplements, vitamins. garlic as a supplement) within 7 days prior to administration of study medication, except for topical products without systemic absorption.
- •Difficulty to swallow study medication.
- •Use of any tobacco products in the 6 months preceding drug administration.
- •Any food allergy, intolerance, restriction or special diet that, in the opinion of the Medical Sub-Investigator, could contraindicate the subject's participation in this study.
- •A depot injection or an implant of any drug within 3 months prior to administration of study medication.
- •Donation of plasma (500 mL) within 7 days prior to drug administration. Donation or loss of whole blood (excluding the volume of blood that will be drawn during the screening procedures of this study) prior to administration of the study medication as follows:
- •50 mL to 300 mL of whole blood within 30 days,
- •301 mL to 500 mL of whole blood within 45 days, or
- •more than 500 mL of whole blood within 56 days prior to drug administration.
研究组 & 干预措施
Bicalutamide 50 mg Tablet
Experimental
干预措施: Bicalutamide 50 mg Tablet vs Casodex® 50 mg Tablet (Drug)
Casodex® 50 mg Tablet
Active Comparator
干预措施: Bicalutamide 50 mg Tablet vs Casodex® 50 mg Tablet (Drug)
结局指标
主要结局
AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration)
时间窗: 144 hour
AUC0-inf area under the concentration-time curve from time zero to infinity)
时间窗: 144 hour
Cmax (maximum observed concentration of drug substance in plasma)
时间窗: 144 hour
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex® 50 mg Tablet in Healthy Subjects Under Fed ConditionsHealthyNCT01044706Kremers Urban Development Company60
已完成
1 期
Study of Bicalutamide 1 x 50 mg Tablet in Healthy Subjects Under Fed ConditionsHealthyNCT00972855Teva Pharmaceuticals USA60
已完成
1 期
Study of Bicalutamide 1 x 50 mg Tablet in Healthy Subjects Under Fasting ConditionsHealthyNCT00973050Teva Pharmaceuticals USA60
尚未招募
Unknown
Bioequivalence study of Bicalutomide 50 mgIRCT20220111053692N15Iran Hormone pharmaceutical Co.24
已完成
1 期
Clindamycin 300 mg Capsules in Healthy Subjects Under Fed ConditionsHealthyNCT00836004Teva Pharmaceuticals USA24